Geer - Novan Senior Vice President and CTO
| NOVNDelisted Stock | USD 0.03 0.01 33.46% |
President
Mr. W. Kent Geer is a Independent Director of the Company. He has served as a member of our board of directors since 2015. Mr. Geer was an audit partner with Ernst Young LLP from 1989 to 2011. Beginning in 2012, Mr. Geer served as the Chairman of the board of directors of PowerSecure International, Inc. until the successful sale of the company in May 2016. since 2015.
| Age | 61 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 919 485 8080 |
| Web | https://www.novan.com |
Novan Management Efficiency
The company has return on total asset (ROA) of (0.2584) % which means that it has lost $0.2584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9889) %, meaning that it created substantial loss on money invested by shareholders. Novan's management efficiency ratios could be used to measure how well Novan manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.93 M in liabilities with Debt to Equity (D/E) ratio of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novan Inc has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Novan until it has trouble settling it off, either with new capital or with free cash flow. So, Novan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novan Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novan to invest in growth at high rates of return. When we think about Novan's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jeremy Hayden | Plus Therapeutics | 48 | |
| Stephen Machatha | Aldeyra | 47 | |
| Steven Kesten | Plus Therapeutics | N/A | |
| Laurent Harvey | Acasti Pharma | N/A | |
| JeanFrancois Boily | Acasti Pharma | N/A | |
| Eckhard Gunther | Aeterna Zentaris | N/A | |
| Michael Teifel | Aeterna Zentaris | N/A | |
| Leslie Auld | Aeterna Zentaris | N/A | |
| Dennis Turpin | Aeterna Zentaris | N/A | |
| Harlan Waksal | Acasti Pharma | 60 | |
| Keith Santorelli | Aeterna Zentaris | N/A | |
| Seijiro Shirahama | Plus Therapeutics | 59 | |
| Genevieve Lemaire | Aeterna Zentaris | N/A | |
| Bonne Adams | TRACON Pharmaceuticals | 47 | |
| Alan Lins | Plus Therapeutics | N/A | |
| David McMullin | Aldeyra | N/A | |
| Massimo MBA | Jaguar Animal Health | 66 | |
| Richard Sachse | Aeterna Zentaris | N/A | |
| Robert Erwin | Ibio Inc | 64 | |
Management Performance
| Return On Equity | -20.99 | |||
| Return On Asset | -0.26 |
Novan Inc Leadership Team
Elected by the shareholders, the Novan's board of directors comprises two types of representatives: Novan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novan. The board's role is to monitor Novan's management team and ensure that shareholders' interests are well served. Novan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Palmour, Independent Director | ||
| Paula MPH, CEO Pres | ||
| Paula Stafford, Chief Development Officer | ||
| Robert Ingram, Independent Chairman of the Board | ||
| Carri Geer, Senior Vice President and CTO | ||
| JD BS, VP RD | ||
| Machelle Sanders, Director | ||
| Richard Peterson, CFO | ||
| Stanley Hollenbach, Senior Vice President - Research and Development | ||
| Geer, Independent Director | ||
| John Gay, Principal Financial Officer, Secretary | ||
| Andrew Novak, Vice President Chief Accounting Officer and Principal Accounting Officer | ||
| MBA MD, Chief Officer | ||
| Robert Keegan, Independent Director | ||
| William Hodges, Interim CFO, Princiapl Financial Officer, Principal Accounting Officer | ||
| Sean Murphy, Independent Director | ||
| Kelly Martin, Independent Director | ||
| Nathan Stasko, President CEO, Director | ||
| Jeff Hunter, Vice President - Technical Operations | ||
| Cole Ikkala, Communications Relations | ||
| John Donofrio, COO VP | ||
| Eugene Sun, Director | ||
| Joyce Rico, Chief Medical Officer | ||
| Elizabeth Messersmith, Chief Development Officer | ||
| G Martin, Interim CEO, Director | ||
| Brian Johnson, Chief Commercial Officer | ||
| John CPA, CFO Sec |
Novan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.99 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.59) % | |||
| Current Valuation | 27.74 M | |||
| Shares Outstanding | 28.02 M | |||
| Shares Owned By Insiders | 0.86 % | |||
| Shares Owned By Institutions | 14.93 % | |||
| Number Of Shares Shorted | 462.95 K | |||
| Price To Earning | (1.49) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Novan Stock
If you are still planning to invest in Novan Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Novan's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |